Valneva SE (VALN) Capital Expenditures (2021 - 2026)
Valneva SE's (VALN) quarterly Capital Expenditures came in at -$289174.2 in Q1 2026, up 80.39% year-on-year from -$160303.6 in Q1 2025, and down 103.2% quarter-over-quarter from $9.0 million in Q4 2025.
Valneva SE (VALN) Capital Expenditures (2021 - 2026) Analysis & Trends
Valneva SE has disclosed Capital Expenditures across 6 years of filings, most recently posting -$289174.2 for Q1 2026.
- Capital Expenditures for Q1 2026 came in at -$289174.2, up 80.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.5 million (down 63.7% YoY), and the FY2025 annual result was $5.1 million, down 65.27% from the prior year.
- Capital Expenditures came in at -$289174.2 for Q1 2026 at Valneva SE, down from $9.0 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $7.8 billion in Q3 2023 to a low of -$7.8 billion in Q2 2023.
- The 5-year median for Capital Expenditures is -$1.4 million (2025), against an average of $3.6 million.
- Peak annual rise in Capital Expenditures reached 118555.13% in 2023, while the deepest fall reached 111166.8% in 2023.
- Valneva SE's Capital Expenditures stood at $52.8 million in 2022, then sank by 53.95% to $24.3 million in 2023, then advanced by 4.97% to $25.5 million in 2024, then plunged by 64.61% to $9.0 million in 2025, then sank by 103.2% to -$289174.2 in 2026.
- The last three Capital Expenditures figures came in at -$289174.2 (Q1 2026), $9.0 million (Q4 2025), and -$780928.8 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -63,220.27 |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | -289,174.18 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -289,174.18 |
| Mar 31, 2026 | -289,174.18 |
| Dec 31, 2025 | 9.03 Mn |
| Dec 31, 2025 | 9.03 Mn |
| Sep 30, 2025 | -780,928.80 |
| Sep 30, 2025 | -780,928.80 |
| Jun 30, 2025 | -1.43 Mn |
| Jun 30, 2025 | -1.43 Mn |
| Mar 31, 2025 | -1.47 Mn |
| Mar 31, 2025 | -1.47 Mn |
| Dec 31, 2024 | 25.51 Mn |
| Dec 31, 2024 | 25.51 Mn |
| Sep 30, 2024 | -6.48 Mn |
| Sep 30, 2024 | -6.48 Mn |
| Jun 30, 2024 | 424,293.71 |
| Jun 30, 2024 | 424,293.71 |
| Mar 31, 2024 | -4.89 Mn |
| Mar 31, 2024 | -4.89 Mn |
| Dec 31, 2023 | 24.30 Mn |
| Dec 31, 2023 | 24.30 Mn |